Walvax Biotechnology Co

Walvax Biotechnology Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Walvax Biotechnology Co (300142.SZ) as of Oct 20, 2026 is -8.54 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 342.22 % — a change of -102.49% (lower).

FCF Conversion

-8.54 %

YoY

-102.49%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Walvax Biotechnology Co is 2025 -8.54 % . FCF Conversion Rate (FCF/EBITDA) of Walvax Biotechnology Co was 2024 342.22 % . It decreases by -102.49% lower compared to the previous year.

The Walvax Biotechnology Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-27.96 CNY
Jan 1, 2019
-204.13 CNY
Jan 1, 2020
-29.20 CNY
Jan 1, 2021
-93.09 CNY
Jan 1, 2022
15.14 CNY
Jan 1, 2023
44.89 CNY
Jan 1, 2024
342.22 CNY
Jan 1, 2025
-8.54 CNY
The Walvax Biotechnology Co FCF Conversion history
YEARFCF ConversionYoY
-8.54 %-102.49%
342.22 %+662.39%
44.89 %+196.49%
15.14 %-116.26%
-93.09 %+218.81%
-29.20 %-85.69%
-204.13 %+629.98%
-27.96 %-144.02%
63.52 %-113.16%
-482.80 %-1,314.93%
39.74 %-118.61%
-213.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Walvax Biotechnology Co Stock analysis

What does Walvax Biotechnology Co do? Walvax Biotechnology Co Ltd is a leading Chinese biotech company specializing in the research, development, production, and marketing of vaccines, antibodies, and diagnostic reagents. The company was founded in 2001 and is headquartered in Beijing. Over the past 20 years, the company has become one of the largest and most advanced biotech companies in the country, capable of offering high-quality and cost-effective products. Walvax Biotechnology is committed to promoting public health and improving people's quality of life. The business model of Walvax Biotechnology is based on the integration of research and development, production, and distribution. The company offers a wide range of products and services and works closely with government agencies and other partners to improve healthcare in China and abroad. The company has various segments, including research and development, vaccine and biological drug production, diagnostic reagent production, and the distribution of medical devices and products. The research and development sector of Walvax Biotechnology has enabled the company to develop a variety of vaccines and biological drugs that contribute to the prevention and treatment of diseases. Some of the company's key vaccines include the Hepatitis A vaccine, Hepatitis E vaccine, rabies vaccine, varicella vaccine, and polio vaccine. In addition, the company has also developed antibody products that can be used for the treatment of cancer and other diseases. Some of the company's key products include the humanized monoclonal antibody against Epidermal Growth Factor Receptor (EGFR) and the humanized monoclonal antibody against Programmed Death-1 (PD-1) receptor. Walvax Biotechnology is also a major producer of diagnostic reagents used for the identification of infections and other diseases. Some of the company's key products include the HIV-ELISA test, HCV-ELISA test, and HBsAg-ELISA test. The distribution sector of Walvax Biotechnology includes the sale of medical devices and products such as blood collection needles and infusion sets. The company has also established partnerships with other companies and organizations to promote the sales and distribution of its products on an international level. Overall, Walvax Biotechnology Co Ltd has become one of China's leading biotech companies. The company has a strong presence in the vaccine industry and has gained a reputation as an innovator and producer of high-quality products. The company is committed to continuing to grow and expand its range of products and services to make a positive contribution to public health. Walvax Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Walvax Biotechnology Co stock

FCF Conversion Rate (FCF/EBITDA) of Walvax Biotechnology Co is -8.54 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Walvax Biotechnology Co changed from 342.22 % to -8.54 %, representing a -102.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Walvax Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Walvax Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Walvax Biotechnology Co

All Key Metrics — Walvax Biotechnology Co